Background

Serina has a background in both business and science and has worked with the Burnet Institute since 2005 primarily sourcing commercial investment and translational funding for early stage R&D.

Involved in the preparation of translational grant applications, Serina is also responsible for the negotiation of commercial deals and collaboration agreements, as well as the identification of translational opportunities of strategic importance within the Institute.

Appointments

• Board member of AusBiotech Ltd
• Member of the Investment Review Committee for the Medical Research Commercialisation Fund

Positions

• Secretary of the Burnet Institute Board’s IP and Commercialisation Committee

Qualifications

• Masters of Business Administration (Executive Program)
• Graduate of Australian Institute of Company Directors
• BSc (Hons), Melbourne University, Victoria, Australia
• BCom, Melbourne University, Australia

Projects (2)

Current (2)

• Access Point Of Care Initiative
  Increasing access to life-saving treatments for infectious diseases through point-of-care tests.
• Improved point-of-care test to eliminate congenital syphilis
  Optimising and validating an innovative test to enable immediate treatment at the point of care.

News Articles (12)

2020 (2)

• Burnet's EVE-M team celebrating the International Day of Women and Girls in Science
• EVE-M: Transforming women's health

2019 (2)

• NHMRC Research Excellence Award for sepsis diagnostic test
• New collaboration targets newborn sepsis

2018 (3)

• New qDOS Lab opens new pathways to market
• Burnet looking forward on World Sepsis Day
• HIV research accelerated

2016 (1)

• Burnet hosts Nanjing delegation

2014 (2)

• Funding boost for fight against syphilis
• Serina Cucuzza to AusBiotech board

2012 (2)

• Boosting the commercialisation of biomedical research
• Super Trade Mission to China a success for Burnet